Refine
Has Fulltext
- yes (488)
Is part of the Bibliography
- no (488)
Keywords
- prostate cancer (17)
- Heavy Ion Experiments (13)
- radical prostatectomy (12)
- Hadron-Hadron scattering (experiments) (11)
- bladder cancer (10)
- growth (6)
- integrins (6)
- Prostate cancer (5)
- Heavy-ion collision (4)
- chemotherapy (4)
- curcumin (4)
- invasion (4)
- metastatic prostate cancer (4)
- mortality (4)
- sulforaphane (4)
- 177Lu-PSMA-617 (3)
- Adenocarcinoma (3)
- FFLU (3)
- PSMA (3)
- Squamous cell carcinoma (3)
- Variant histology (3)
- external beam radiotherapy (3)
- primary prostate cancer (3)
- proliferation (3)
- survival (3)
- systematic biopsy (3)
- Bladder cancer (2)
- CD44 (2)
- CSM (2)
- Cancer-specific mortality (2)
- Epidemiology and End Results (2)
- HoLEP (2)
- Melanoma (2)
- NCCN (2)
- PSA (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Penile cancer (2)
- Radical prostatectomy (2)
- SCC (2)
- Surveillance (2)
- Urethral cancer (2)
- adhesion (2)
- cancer-specific mortality (2)
- concordance (2)
- contemporary (2)
- fusion biopsy (2)
- immunohistochemistry (2)
- kidney cancer (2)
- localized prostate cancer (2)
- mTOR (2)
- other-cause mortality (2)
- overall survival (2)
- radical prostatecomy (2)
- renal cell cancer (2)
- resistance (2)
- tumor growth (2)
- upgrading (2)
- urological cancer (2)
- very high risk (2)
- 223Radium-dichloride (1)
- AKT-mTOR pathway (1)
- ASAP (1)
- Acute kidney injury (1)
- Akt-mTOR pathway (1)
- Akt-mTOR signaling (1)
- Anticoagulation (1)
- Artificial intelligence (1)
- Awareness campaign (1)
- BMI (1)
- BPH (1)
- BPO (1)
- Bleeding (1)
- CDK-cyclin axis (1)
- CRPC (1)
- Cancer check up (1)
- Cancer therapy (1)
- Cancer-specific survival (1)
- Checkpoint inhibitor (1)
- Chemoprevention (1)
- Clavien–Dindo classification (1)
- Complications (1)
- Cystatin C (1)
- Dietary HDAC inhibitor (1)
- Downgrading (1)
- D’Amico classification (1)
- EBRT (1)
- Electroweak interaction (1)
- External beam radiotherapy (1)
- Extraprostatic (1)
- Functional outcomes (1)
- GFR (1)
- Geographical disparities (1)
- Gleason Grade group (1)
- Gleason Score (1)
- Gleason grade group (1)
- Gleason score (1)
- Gleason upgrading (1)
- HDAC (1)
- HOLEP (1)
- Hematologic adverse events (1)
- Hematotoxicity (1)
- High-risk prostate cancer (1)
- Hispanic–Latino race/ethnicity (1)
- Histology (1)
- Holmium laser enucleation (1)
- IGF-1 (1)
- IHC (1)
- IPSS (1)
- Immunotherapy (1)
- Incidence rate (1)
- Incidental prostate cancer (1)
- Intermediate-risk (1)
- Keap1-Nrf2 (1)
- Lee type, functional outcome (1)
- Lepton-Nucleon Scattering (experiments) (1)
- Local therapy (1)
- Locally advanced (1)
- Long-term continence (1)
- Machine learning (1)
- Metastasis-directed therapy (1)
- Metastatic castration-resistant prostate cancer (1)
- Mortality (1)
- Multiparametric MRI (1)
- NVBP (1)
- Nephrectomy (1)
- NeuroSAFE (1)
- Nivolumab (1)
- Non-urothelial (1)
- OR time (1)
- ORP (1)
- Oligometastatic (1)
- Organ-confined (1)
- PAD-test (1)
- PD-1 inhibitor (1)
- PROM (1)
- PSA screening (1)
- PSA-Screening (1)
- Positron-emission tomography (1)
- Preventive medicine (1)
- Prostata-specific antigen (1)
- Prostataspezifisches Antigen (1)
- Prostate-specific membrane antigen (1)
- Prostatic neoplasms (1)
- Prävention (1)
- QOL (1)
- RARP (1)
- ROS (1)
- Race (1)
- Radical cystectomy (1)
- Radiomics (1)
- Radiotherapy (1)
- Region (1)
- Renal cell carcinoma (1)
- Robotic-assisted radical prostatectomy (1)
- SEER (1)
- Salvage therapy (1)
- Single positive core biopsy (1)
- Social differences (1)
- Stage at presentation (1)
- Sulphoraphane (1)
- Systemic therapy (1)
- TUR-P (1)
- Time trend (1)
- Transfusion (1)
- Transitional cell carcinoma (1)
- Transurethral resection of the prostate (1)
- Treatment rates (1)
- Upgrading (1)
- Urinary continence (1)
- Urinary incontinence (1)
- Urologic tumors (1)
- Urothelial cancer (1)
- Vorsorgeuntersuchung (1)
- adjuvant chemotherapy (1)
- amygdalin (1)
- antibiotic treatment (1)
- bioavailability (1)
- biopsy (1)
- biopsy cores (1)
- biopsy naïve (1)
- blood loss (1)
- bone barrow (1)
- buccal mucosal graft urethroplasty (1)
- cabazitaxel (1)
- cabozantinib (1)
- cancer specific survival (1)
- cancer-specific survival (1)
- castration resistance (1)
- catheter (1)
- catheter removal (1)
- cdk (1)
- cell cycling (1)
- cell growth (1)
- chemoprotection (1)
- chemoresistance (1)
- chemotaxis (1)
- colon cancer (1)
- complementary/alternative medicine (CAM) (1)
- complication (1)
- complications (1)
- consensus classification (1)
- correlation (1)
- cyclins (1)
- deferred treatment (1)
- delayed treatment (1)
- diffuse marrow involvement (1)
- docetaxel (1)
- double negative (1)
- downgrading (1)
- drug resistance (1)
- early continence (1)
- elderly (1)
- endothelial cells (1)
- epididymitis (1)
- everolimus (1)
- functional outcome (1)
- heart (1)
- hepatocellular carcinoma (1)
- high risk (1)
- high-risk (1)
- histological outcomes (1)
- histone deacetylase (1)
- human (1)
- incontinence (1)
- infection (1)
- intermediate risk (1)
- inverse stage migration (1)
- kidney (1)
- light irradiation (1)
- liver (1)
- local treatment (1)
- low risk (1)
- lung cancer (1)
- lymph node dissection (1)
- mCRPC (1)
- mechanistic target of rapamycin (mTOR) (1)
- metastasis (1)
- metastatic castration-resistant prostate cancer (1)
- metastatic urethral cancer (1)
- molecular subtyping (1)
- mpMRI (1)
- mtor (1)
- multiparametric magnetic resonance imaging (1)
- nerve-sparing (1)
- nerve-sparing surgery (1)
- neurovascular bundle preservation (1)
- non-organ confined stage (1)
- olive mill wastewater (OMWW) (1)
- open (1)
- other cause mortality (1)
- outcomes (1)
- overtreatment (1)
- oxidative stress (1)
- pad-test (1)
- patient-reported outcome measure (1)
- perioperative outcome (1)
- prehabilitation (1)
- prognosis (1)
- prostate neoplasm (1)
- prostate volume (1)
- prostate-specific antigen (1)
- race/ethnicity disparities (1)
- radiation (1)
- radical cystectomy (1)
- renal cell carcinoma (1)
- repeat biopsy (1)
- resistant cell lines (1)
- risk score (1)
- robotic-assisted (1)
- salvage radical prostatectomy (1)
- second-line (1)
- secondary cancer (1)
- sexual dysfunction (1)
- sexual rehabilitation (1)
- stage (1)
- suprapubic catheter (1)
- surgical complications (1)
- surgical margin (1)
- targeted biopsy (1)
- temsirolimus (1)
- temsirolimus-resistance (1)
- transrectal prostate biopsy (1)
- transurethral catheter (1)
- tumor adhesion (1)
- tumor migration (1)
- tumor proliferation (1)
- tumor weight (1)
- tyrosine kinase inhibitors (1)
- upstaging (1)
- urethral stricture (1)
- urethroplasty (1)
- urinary incontinence (1)
- valproic acid (1)
- very high-risk (1)
- waiting time (1)
- Öffentlichkeit (1)
Institute
- Physik (412)
- Frankfurt Institute for Advanced Studies (FIAS) (373)
- Informatik (358)
- Medizin (76)
- Biowissenschaften (1)
- Informatik und Mathematik (1)
Inclusive ϒ(1S) and ϒ(2S) production have been measured in Pb–Pb collisions at the centre-of-mass energy per nucleon–nucleon pair √sNN = 5.02 TeV, using the ALICE detector at the CERN LHC. The ϒ mesons are reconstructed in the centre-of-mass rapidity interval 2.5 < y < 4 and in the transversemomentum range pT < 15 GeV/c, via their decays to muon pairs. In this Letter, we present results on the inclusive ϒ(1S) nuclear modification factor RAA as a function of collision centrality, transverse momentum and rapidity. The ϒ(1S) and ϒ(2S) RAA, integrated over the centrality range 0–90%, are 0.37± 0.02(stat) ± 0.03(syst) and 0.10 ± 0.04(stat) ± 0.02(syst), respectively, leading to a ratio Rϒ(2S) AA /Rϒ(1S) AA of 0.28±0.12(stat)±0.06(syst). The observed ϒ(1S) suppression increases with the centrality of the collision and no significant variation is observed as a function of transverse momentum and rapidity.
Inclusive Υ(1S) and Υ(2S) production have been measured in Pb-Pb collisions at the centre-of-mass energy per nucleon-nucleon pair sNN−−−√=5.02 TeV, using the ALICE detector at the CERN LHC. The Υ mesons are reconstructed in the centre-of-mass rapidity interval 2.5<y<4 and in the transverse-momentum range pT<15 GeV/c, via their decays to muon pairs. In this Letter, we present results on the inclusive Υ(1S) nuclear modification factor RAA as a function of collision centrality, transverse momentum and rapidity. The Υ(1S) and Υ(2S) RAA, integrated over the centrality range 0-90%, are 0.37±0.02(stat)±0.03(syst) and 0.10±0.04(stat)±0.02(syst), respectively, leading to a ratio RΥ(2S)AA/RΥ(1S)AA of 0.28±0.12(stat)±0.06(syst). The observed Υ(1S) suppression increases with the centrality of the collision and no significant variation is observed as a function of transverse momentum and rapidity.
Inclusive Υ(1S) and Υ(2S) production have been measured in Pb-Pb collisions at the centre-of-mass energy per nucleon-nucleon pair sNN−−−√=5.02 TeV, using the ALICE detector at the CERN LHC. The Υ mesons are reconstructed in the centre-of-mass rapidity interval 2.5<y<4 and in the transverse-momentum range pT<15 GeV/c, via their decays to muon pairs. In this Letter, we present results on the inclusive Υ(1S) nuclear modification factor RAA as a function of collision centrality, transverse momentum and rapidity. The Υ(1S) and Υ(2S) RAA, integrated over the centrality range 0-90%, are 0.37±0.02(stat)±0.03(syst) and 0.10±0.04(stat)±0.02(syst), respectively, leading to a ratio RΥ(2S)AA/RΥ(1S)AA of 0.28±0.12(stat)±0.06(syst). The observed Υ(1S) suppression increases with the centrality of the collision and no significant variation is observed as a function of transverse momentum and rapidity.
ϒ production in p–Pb interactions is studied at the centre-of-mass energy per nucleon–nucleon collision √sNN = 8.16 TeV with the ALICE detector at the CERN LHC. The measurement is performed reconstructing bottomonium resonances via their dimuon decay channel, in the centre-of-mass rapidity intervals 2.03 < ycms < 3.53 and −4.46 < ycms < −2.96, down to zero transverse momentum. In this work, results on the ϒ(1S) production cross section as a function of rapidity and transverse momentum are presented. The corresponding nuclear modification factor shows a suppression of the ϒ(1S) yields with respect to pp collisions, both at forward and backward rapidity. This suppression is stronger in the low transverse momentum region and shows no significant dependence on the centrality of the interactions. Furthermore, the ϒ(2S) nuclear modification factor is evaluated, suggesting a suppression similar to that of the ϒ(1S). A first measurement of the ϒ(3S) has also been performed. Finally, results are compared with previous ALICE measurements in p–Pb collisions at √sNN = 5.02 TeV and with theoretical calculations.
Υ production in p-Pb interactions is studied at the centre-of-mass energy per nucleon-nucleon collision sNN−−−√ = 8.16 TeV with the ALICE detector at the CERN LHC. The measurement is performed reconstructing bottomonium resonances via their dimuon decay channel, in the centre-of-mass rapidity intervals 2.03<ycms<3.53 and −4.46<ycms<−2.96, down to zero transverse momentum. In this work, results on the inclusive Υ(1S) production cross section as a function of rapidity and transverse momentum are presented. The corresponding nuclear modification factor shows a suppression of the Υ(1S) yields with respect to pp collisions, both at forward and backward rapidity. This suppression is stronger in the low transverse momentum region and shows no significant dependence on the centrality of the interactions. Furthermore, the Υ(2S) nuclear modification factor is also evaluated, suggesting a suppression similar to that of the Υ(1S). A first measurement of the Υ(3S) has also been performed. Finally, results are compared with previous measurements performed by ALICE in p-Pb collisions at sNN−−−√ = 5.02 TeV and with theoretical calculations.
Υ production in p-Pb interactions is studied at the centre-of-mass energy per nucleon-nucleon collision sNN−−−√ = 8.16 TeV with the ALICE detector at the CERN LHC. The measurement is performed reconstructing bottomonium resonances via their dimuon decay channel, in the centre-of-mass rapidity intervals 2.03<ycms<3.53 and −4.46<ycms<−2.96, down to zero transverse momentum. In this work, results on the inclusive Υ(1S) production cross section as a function of rapidity and transverse momentum are presented. The corresponding nuclear modification factor shows a suppression of the Υ(1S) yields with respect to pp collisions, both at forward and backward rapidity. This suppression is stronger in the low transverse momentum region and shows no significant dependence on the centrality of the interactions. Furthermore, the Υ(2S) nuclear modification factor is also evaluated, suggesting a suppression similar to that of the Υ(1S). A first measurement of the Υ(3S) has also been performed. Finally, results are compared with previous measurements performed by ALICE in p-Pb collisions at sNN−−−√ = 5.02 TeV and with theoretical calculations.
ϒ production and nuclear modification at forward rapidity in Pb–Pb collisions at √sNN = 5.02TeV
(2021)
The production of ϒ mesons in Pb–Pb collisions at a centre-of-mass energy per nucleon pair √sNN = 5.02 TeV is measured with the muon spectrometer of the ALICE detector at the LHC. The yields as well as the nuclear modification factors are determined in the forward rapidity region 2.5 < y < 4.0, as a function of rapidity, transverse momentum and collision centrality. The results show that the production of the ϒ(1S) meson is suppressed by a factor of about three with respect to the production in proton–proton collisions. For the first time, a significant signal for the ϒ(2S) meson is observed at forward rapidity, indicating a suppression stronger by about a factor 2–3 with respect to the ground state. The measurements are compared with transport, hydrodynamic, comover and statistical hadronisation model calculations.
ϒ production and nuclear modification at forward rapidity in Pb–Pb collisions at √sNN = 5.02 TeV
(2021)
The production of Υ mesons in Pb-Pb collisions at a centre-of-mass energy per nucleon pair sNN−−−√ = 5 TeV is measured with the muon spectrometer of the ALICE detector at the LHC. The yields as well as the nuclear modification factors are determined in the forward rapidity region 2.5<y<4.0, as a function of rapidity, transverse momentum and collision centrality. The results show that the production of the Υ(1S) meson is suppressed by a factor of about three with respect to the production in proton-proton collisions. For the first time, a significant signal for the Υ(2S) meson is observed at forward rapidity, indicating a suppression stronger by about a factor 2-3 with respect to the ground state. The measurements are compared with transport, hydrodynamic, comover and statistical hadronisation model calculations.
ϒ production and nuclear modification at forward rapidity in Pb–Pb collisions at √sNN = 5.02 TeV
(2020)
The production of Υ mesons in Pb-Pb collisions at a centre-of-mass energy per nucleon pair sNN−−−√ = 5 TeV is measured with the muon spectrometer of ALICE at the LHC. The yields as well as the nuclear modification factors are determined in the forward rapidity region 2.5<y<4.0, as a function of rapidity, transverse momentum and collision centrality. The results show that the production of Υ(1S) is suppressed by a factor of about three with respect to the production in proton-proton collisions. For the first time, a significant Υ(2S) signal is observed at forward rapidity, indicating a suppression stronger by about a factor 2-3 with respect to the ground state. The measurements are compared with transport, hydrodynamic, comover and statistical hadronisation model calculations.
The first measurements of the scattering parameters of ΛK pairs in all three charge combinations (ΛK+, ΛK−, and ΛK0S) are presented. The results are achieved through a femtoscopic analysis of ΛK correlations in Pb-Pb collisions at sNN−−−√ = 2.76 TeV recorded by ALICE at the LHC. The femtoscopic correlations result from strong final-state interactions, and are fit with a parametrization allowing for both the characterization of the pair emission source and the measurement of the scattering parameters for the particle pairs. Extensive studies with the THERMINATOR 2 event generator provide a good description of the non-femtoscopic background, which results mainly from collective effects, with unprecedented precision. Furthermore, together with HIJING simulations, this model is used to account for contributions from residual correlations induced by feed-down from particle decays. The extracted scattering parameters indicate that the strong force is repulsive in the ΛK+ interaction and attractive in the ΛK− interaction. The data hint that the and ΛK0S interaction is attractive, however the uncertainty of the result does not permit such a decisive conclusion. The results suggest an effect arising either from different quark-antiquark interactions between the pairs (ss¯ in ΛK+ and uu¯¯¯ in ΛK−) or from different net strangeness for each system (S = 0 for ΛK+, and S = −2 for ΛK−). Finally, the ΛK systems exhibit source radii larger than expected from extrapolation from identical particle femtoscopic studies. This effect is interpreted as resulting from the separation in space-time of the single-particle Λ and K source distributions.